CTLA4 and central nervous system cancer: For example, higher mutational load (top 20% highest TMB quintile) predicts better survival across diverse cancer types tested, except for glioma, and this is relevant in patients treated with either anti-PD-1 (programmed cell death protein 1) or anti-CTLA-4 (cytotoxic T lymphocyte-associated antigen-4) therapies [3].